GLPwatch
Papers (12034)
Page 149 of 201, ranked by citation count.
- Improving beta-cell secretory function and glycaemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, continuous glucose monitor-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide.
- Choosing among the incretin agents and why it matters.
- Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study.
- Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.
- Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease.
- Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD).
- Semaglutide - properties, action and chromatographic analysis.
- Glucagon-like peptide-1 agonists.
- Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.
- Portal vein thrombosis in a patient on semaglutide.
- The prospective record-breaking obesity drug tirzepatide raises concerns about affordability.
- Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis.
- Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial.
- Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.
- The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease.
- Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients.
- Liraglutide is an effective drug for the treatment of obesity also in real life.
- Activation of GLP-1R ameliorates microglial pyroptosis after spinal cord injury by restoring FANCC expression.
- Shift of Glucose Peak Time During Oral Glucose Tolerance Test is Associated with Changes in Insulin Secretion and Insulin Sensitivity After Therapy with Antidiabetic Drugs in Patients with Type 2 Diabetes.
- Incretin based therapeutics: connections to vascular biology and implications for potential cardiovascular disease prevention: Editorial to: "Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation" by Dai et al.
- Obesity Treatment: A Focus on Pharmacotherapy of Weight Management.
- Combined GPR40 and GPR119 full agonism with K-757 and K-833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM.
- Real-life use of liraglutide 3 mg in obesity management: The SAX-RL study.
- NHS England consults on rolling out obesity injection tirzepatide to meet demand.
- Semaglutide cuts kidney risk in obesity.
- Research digest.
- Semaglutide and the retina: Weighing evidence against concern.
- Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
- A GLP-1 receptor agonist semaglutide attenuates cardiac microvascular injury in HFD/STZ-induced diabetic mice.
- Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis.
- Positron emission tomography to assess drug occupancy at peripheral and central incretin receptors.
- Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
- Clinical experience with exenatide in a routine secondary care diabetes clinic.
- Effect of Glucagon-like peptide-1 agonist (liriglutide) on weight and glycemic control among adults with type 2 diabetes mellitus attending primary care center at security forces hospital in Riyadh, Saudi Arabia.
- A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.
- Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ).
- REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.
- Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult rats.
- Surpassing insulin glargine in type 2 diabetes with tirzepatide.
- Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens.
- SEMAGLUTIDE: Weight loss, glycaemic control and safety profile in obese patients with and without type-II diabetes-An experience from Karachi, Pakistan.
- [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
- Eligibility for Semaglutide 2.4 mg in Patients With Acute Myocardial Infarction and Overweight or Obesity Without Diabetes: A Real-World Analysis.
- Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk.
- Bridging the Gap Between Diabetes and Cardiovascular Disease: A Comparative Review of Different Glucagon-Like Peptide-1 (GLP-1) Agonists: Efficacy, Safety, and Patient Outcomes.
- Semaglutide in Heart Failure With Preserved Ejection Fraction: Benefits Above and Beyond Weight Loss.
- Interplay of childhood metabolic dysfunction-associated steatotic liver disease and obesity in the development of youth-onset type 2 diabetes.
- Advances in neurological therapies: A review of clinical trials in Alzheimer's, Parkinson's, and multiple sclerosis.
- A case of euglycaemic diabetic ketoacidosis in a T2DM patient using Tirzepatide.
- Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials.
- Multi-pathway-driven hepatic protection: Semaglutide combined with HIIT counteracts diabetic liver injury in db/db mice.
- GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease.
- Semaglutide and weight loss - A concern for diabetics and pharmaceuticals.
- The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus.
- Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi).
- The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review.
- Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.
- GLP-1 Receptor Agonist-Associated Slimmer's Palsy: Implications for the Peripheral Nerve Surgeon.
- The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.
- Efficacy of Semaglutide as Adjuvant Treatment for Sleeve Gastrectomy: A Proof-of-Concept Study in Mice.